NDAORALTABLET
Approved
May 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
AXID AR (nizatidine) by GSK is clinical pharmacology nizatidine is a competitive, reversible inhibitor of histamine at the histamine h 2 -receptors, particularly those in the gastric parietal cells. Approved for schizophrenia. First approved in 1996.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AXID AR (nizatidine) is an oral H2-receptor antagonist that competitively inhibits histamine at gastric parietal cells to reduce acid secretion. It is indicated for schizophrenia and significantly inhibits nocturnal and meal-stimulated gastric acid output for up to 12 hours. The drug exhibits rapid oral bioavailability exceeding 70% with a short half-life of 1-2 hours.
LOE Approaching
Product is approaching loss of exclusivity with minimal linked commercial roles, indicating a contracting team footprint and reduced career development opportunities.
Mechanism of Action
CLINICAL PHARMACOLOGY Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H 2 -receptors, particularly those in the gastric parietal cells. Antisecretory Activity Effects on Acid Secretion Nizatidine significantly inhibited nocturnal gastric acid secretion for up to 12…
Worked on AXID AR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.